Efgartigimod Sustains Sjögren's Disease Control Through 48 Weeks in RHO+ OLEByIsabelle Peene, MD, PhDJune 26th 2026
Autoantibody and IFN Burden Correlate With Nipocalimab Response in Sjögren's DiseaseByR. Hal Scofield, MDJune 10th 2026
Joint Ventures: The B-Cell Story, Part 2 — Ianalumab and the Next Chapter in Sjögren's and LupusByRihards Buss, MD,Jack Arnold, MBBS, MRCP, PhD,Lucy Carter, MBBS, PhDMay 5th 2026